DK1390389T3 - Cripto-blokerende antistoffer og anvendelser deraf - Google Patents

Cripto-blokerende antistoffer og anvendelser deraf

Info

Publication number: DK1390389T3
Authority: DK; Denmark
Prior art keywords: crypto; blocking antibodies; antibodies; blocking
Prior art date: 2001-04-26

Application number

DK02731384T

Other languages

English (en)

Inventor

Michele Sanicola-Nadel

Kevin Williams

Susan Schiffer

Paul Rayhorn

Original Assignee

Biogen Idec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-26

Filing date

2002-04-17

Publication date

2009-04-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27501437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1390389(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-17 Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc

2009-04-20 Application granted granted Critical

2009-04-20 Publication of DK1390389T3 publication Critical patent/DK1390389T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK02731384T 2001-04-26 2002-04-17 Cripto-blokerende antistoffer og anvendelser deraf DK1390389T3 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US28678201P	2001-04-26	2001-04-26
US29302001P	2001-05-17	2001-05-17
US30109101P	2001-06-26	2001-06-26
US36700202P	2002-03-22	2002-03-22
PCT/US2002/011950 WO2002088170A2 (en)	2001-04-26	2002-04-17	Cripto blocking antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
DK1390389T3 true DK1390389T3 (da)	2009-04-20

Family

ID=27501437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02731384T DK1390389T3 (da)	2001-04-26	2002-04-17	Cripto-blokerende antistoffer og anvendelser deraf

Country Status (33)

Country	Link
US (6)	US7531174B2 (da)
EP (3)	EP1390389B1 (da)
JP (4)	JP4307845B2 (da)
KR (1)	KR100592357B1 (da)
CN (1)	CN100352501C (da)
AR (3)	AR037223A1 (da)
AT (2)	ATE420659T1 (da)
BG (1)	BG108363A (da)
BR (1)	BR0209254A (da)
CA (2)	CA2443840C (da)
CL (1)	CL2009002199A1 (da)
CY (1)	CY1108960T1 (da)
CZ (1)	CZ20033208A3 (da)
DE (1)	DE60230868D1 (da)
DK (1)	DK1390389T3 (da)
EA (1)	EA007469B1 (da)
EE (1)	EE200300528A (da)
ES (1)	ES2321065T3 (da)
GE (1)	GEP20074091B (da)
HU (1)	HUP0501113A3 (da)
IS (1)	IS2662B (da)
MX (1)	MXPA03009797A (da)
MY (2)	MY150237A (da)
NO (1)	NO20034805L (da)
NZ (1)	NZ566268A (da)
PL (1)	PL207087B1 (da)
PT (1)	PT1390389E (da)
RS (2)	RS20110024A (da)
SG (1)	SG157951A1 (da)
SI (1)	SI1390389T1 (da)
SK (1)	SK14432003A3 (da)
TR (1)	TR200301846T2 (da)
WO (1)	WO2002088170A2 (da)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPR395801A0 (en)	2001-03-26	2001-04-26	Austin Research Institute, The	Antibodies against cancer
US20090123470A1 (en) *	2001-03-26	2009-05-14	The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd.	Antibodies Against Cancer
US7582299B2 (en)	2001-04-26	2009-09-01	Biogen Idec Ma Inc.	Cripto-specific antibodies
ATE420659T1 (de)	2001-04-26	2009-01-15	Biogen Idec Inc	Criptoblockierende antikörper und deren verwendung
EP1494693B1 (en) *	2002-03-22	2010-12-08	Biogen Idec MA Inc.	Cripto-specific antibodies
WO2005000898A2 (en)	2003-06-27	2005-01-06	Biogen Idec Ma Inc.	Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
WO2005028433A2 (en) *	2003-09-15	2005-03-31	Research Development Foundation	CRIPTO ANTAGONISM OF ACTIVIN AND TGF-β SIGNALING
PT1725249E (pt)	2003-11-06	2014-04-10	Seattle Genetics Inc	Compostos de monometilvalina capazes de conjugação a ligandos
EP2385069A3 (en)	2003-11-12	2012-05-30	Biogen Idec MA Inc.	Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
BRPI0510883B8 (pt)	2004-06-01	2021-05-25	Genentech Inc	composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
BRPI0516284A (pt)	2004-09-23	2008-09-02	Genentech Inc	anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
US20100111856A1 (en)	2004-09-23	2010-05-06	Herman Gill	Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR20070100346A (ko) *	2005-01-05	2007-10-10	바이오겐 아이덱 엠에이 인코포레이티드	크립토 결합 분자
WO2006074399A2 (en)	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Multispecific binding molecules comprising connecting peptides
WO2008014426A2 (en)	2006-07-28	2008-01-31	Children's Memorial Hospital	Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
AU2008260445A1 (en) *	2007-06-01	2008-12-11	Biogen Idec Ma Inc.	Cripto binding molecules
US20110123443A1 (en) *	2008-04-21	2011-05-26	Merck & Co., Inc.	Pancreatic beta-cell mass biomarker
EP2350131B1 (en) *	2008-11-07	2017-06-07	Research Development Foundation	Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
JP2013504585A (ja)	2009-09-09	2013-02-07	セントローズ，エルエルシー	細胞外標的化薬物複合体
TWI540136B (zh)	2010-04-15	2016-07-01	梅迪繆思有限公司	吡咯并苯并二氮呯及其共軛物
CN103068406B (zh)	2010-06-08	2017-06-30	基因泰克公司	半胱氨酸改造的抗体和偶联物
US20120121615A1 (en)	2010-11-17	2012-05-17	Flygare John A	Alaninyl maytansinol antibody conjugates
CN110038135B (zh)	2011-03-17	2021-03-05	伯明翰大学	重新定向的免疫治疗
US20140127240A1 (en)	2011-04-21	2014-05-08	Bayer Pharma Aktiengesellschaft	Novel Binder-Drug Conjugates (ADCs) and Use of Same
KR101992502B1 (ko)	2011-05-12	2019-06-24	제넨테크, 인크.	프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
WO2013012733A1 (en)	2011-07-15	2013-01-24	Biogen Idec Ma Inc.	Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
BR112014009050B1 (pt)	2011-10-14	2022-06-21	Medimmune Limited	Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas
WO2013130093A1 (en)	2012-03-02	2013-09-06	Genentech, Inc.	Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
EP2839860B1 (en)	2012-10-12	2019-05-01	MedImmune Limited	Pyrrolobenzodiazepines and conjugates thereof
SMT201800346T1 (it)	2012-10-12	2018-09-13	Medimmune Ltd	Coniugati pirrolobenzodiazepina-anticorpo
WO2014057120A1 (en)	2012-10-12	2014-04-17	Adc Therapeutics Sàrl	Pyrrolobenzodiazepine-antibody conjugates
KR101995619B1 (ko)	2012-10-12	2019-07-03	에이디씨 테라퓨틱스 에스에이	피롤로벤조디아제핀-항체 컨주게이트
RS57694B1 (sr)	2012-10-12	2018-11-30	Adc Therapeutics Sa	Pirolobenzodiazepin - anti-psma konjugati antitela
PL2906251T3 (pl)	2012-10-12	2018-02-28	Adc Therapeutics Sa	Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22
WO2014057114A1 (en)	2012-10-12	2014-04-17	Adc Therapeutics Sàrl	Pyrrolobenzodiazepine-anti-psma antibody conjugates
CN110452242A (zh)	2012-12-21	2019-11-15	麦迪穆有限责任公司	吡咯并苯并二氮杂卓及其结合物
CN110627797A (zh)	2012-12-21	2019-12-31	麦迪穆有限责任公司	用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
EA027910B1 (ru)	2013-03-13	2017-09-29	Медимьюн Лимитед	Пирролобензодиазепины и их конъюгаты
WO2014140174A1 (en)	2013-03-13	2014-09-18	Spirogen Sàrl	Pyrrolobenzodiazepines and conjugates thereof
CA2904044C (en)	2013-03-13	2020-03-31	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
BR112016002829A2 (pt)	2013-08-12	2017-09-19	Genentech Inc	Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
EP3054986B1 (en)	2013-10-11	2019-03-20	Medimmune Limited	Pyrrolobenzodiazepine-antibody conjugates
EP3054983B1 (en)	2013-10-11	2019-03-20	Medimmune Limited	Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en)	2013-10-11	2013-11-27	Spirogen Sarl	Pyrrolobenzodiazepines and conjugates thereof
US9950078B2 (en)	2013-10-11	2018-04-24	Medimmune Limited	Pyrrolobenzodiazepine-antibody conjugates
EA201691023A1 (ru)	2013-12-16	2016-10-31	Дженентек, Инк.	Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
CA2929565A1 (en)	2013-12-16	2015-06-25	Genentech, Inc.	1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
MX371092B (es)	2013-12-16	2020-01-16	Genentech Inc	Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
PL3086814T3 (pl)	2013-12-23	2020-12-28	Bayer Pharma Aktiengesellschaft	Koniugaty środka wiążącego (ADC) z inhibitorami KSP
EP3193940A1 (en)	2014-09-10	2017-07-26	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
CN106714844B (zh)	2014-09-12	2022-08-05	基因泰克公司	蒽环类二硫化物中间体、抗体-药物缀合物和方法
GB201416112D0 (en)	2014-09-12	2014-10-29	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
CN107108724A (zh)	2014-09-12	2017-08-29	豪夫迈·罗氏有限公司	半胱氨酸改造抗体和缀合物
JP2017533887A (ja)	2014-09-17	2017-11-16	ジェネンテック，インコーポレイテッド	ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
CN107148285B (zh)	2014-11-25	2022-01-04	Adc治疗股份有限公司	吡咯并苯并二氮杂䓬-抗体缀合物
AU2015358532C1 (en)	2014-12-03	2020-10-29	Genentech, Inc.	Quaternary amine compounds and antibody-drug conjugates thereof
WO2016161477A1 (en) *	2015-04-07	2016-10-13	Prince Henry's Institute Of Medical Research (Acn 132 025 024)	A method of treating neoplasias
GB201506402D0 (en)	2015-04-15	2015-05-27	Berkel Patricius H C Van And Howard Philip W	Site-specific antibody-drug conjugates
GB201506411D0 (en)	2015-04-15	2015-05-27	Bergenbio As	Humanized anti-axl antibodies
EP4406606A3 (de)	2015-06-22	2024-10-09	Bayer Pharma Aktiengesellschaft	Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren g
MA43345A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017060322A2 (en)	2015-10-10	2017-04-13	Bayer Pharma Aktiengesellschaft	Ptefb-inhibitor-adc
MA43354A (fr)	2015-10-16	2018-08-22	Genentech Inc	Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr)	2015-10-20	2018-08-29	Genentech Inc	Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en)	2016-01-26	2016-03-09	Medimmune Ltd	Pyrrolobenzodiazepines
GB201602356D0 (en)	2016-02-10	2016-03-23	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en)	2016-02-10	2016-03-23	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
SG11201808167VA (en)	2016-03-24	2018-10-30	Bayer Pharma AG	Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN108700598A (zh)	2016-03-25	2018-10-23	豪夫迈·罗氏有限公司	多路总抗体和抗体缀合的药物量化测定法
GB201607478D0 (en)	2016-04-29	2016-06-15	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
ES2858151T3 (es)	2016-05-20	2021-09-29	Hoffmann La Roche	Conjugados de PROTAC-anticuerpo y procedimientos de uso
JP7022080B2 (ja)	2016-05-27	2022-02-17	ジェネンテック，インコーポレイテッド	部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
CN109476648B (zh)	2016-06-06	2022-09-13	豪夫迈·罗氏有限公司	司维司群抗体-药物缀合物和使用方法
US11001636B2 (en)	2016-06-15	2021-05-11	Bayer Pharma Aktiengesellschaft	Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
WO2018031662A1 (en)	2016-08-11	2018-02-15	Genentech, Inc.	Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (zh)	2016-10-05	2023-05-16	豪夫迈·罗氏有限公司	制备抗体药物缀合物的方法
GB201617466D0 (en)	2016-10-14	2016-11-30	Medimmune Ltd	Pyrrolobenzodiazepine conjugates
CN110352068A (zh)	2016-12-02	2019-10-18	南加利福尼亚大学	合成的免疫受体及其使用方法
CA3047522A1 (en)	2016-12-21	2018-06-28	Bayer Pharma Aktiengesellschaft	Specific antibody drug conjugates (adcs) having ksp inhibitors
JP7066714B2 (ja)	2016-12-21	2022-05-13	バイエル・ファルマ・アクティエンゲゼルシャフト	酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
KR20190099250A (ko)	2016-12-21	2019-08-26	바이엘 악티엔게젤샤프트	효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
JP6671555B2 (ja)	2017-02-08	2020-03-25	アーデーセーセラピューティクスソシエテアノニム	ピロロベンゾジアゼピン抗体複合体
GB201702031D0 (en)	2017-02-08	2017-03-22	Medlmmune Ltd	Pyrrolobenzodiazepine-antibody conjugates
CN110582505B (zh)	2017-04-18	2021-04-02	免疫医疗有限公司	吡咯并苯并二氮杂*缀合物
MX2019012464A (es)	2017-04-20	2019-12-11	Adc Therapeutics Sa	Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
AU2018285562B2 (en)	2017-06-14	2024-01-18	Adc Therapeutics Sa	Dosage regimes for the administration of an anti-CD19 ADC
ES2906965T3 (es)	2017-08-18	2022-04-21	Medimmune Ltd	Conjugados de pirrolobenzodiazepina
US20200216463A1 (en)	2017-09-20	2020-07-09	Ph Pharma Co., Ltd.	Thailanstatin analogs
GB201803342D0 (en)	2018-03-01	2018-04-18	Medimmune Ltd	Methods
GB201806022D0 (en)	2018-04-12	2018-05-30	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
IL316090A (en)	2018-06-01	2024-12-01	Eisai R&D Man Co Ltd	Antibody-drug conjugates of splicing modulators and methods of use
GB201814281D0 (en)	2018-09-03	2018-10-17	Femtogenix Ltd	Cytotoxic agents
CA3115110A1 (en)	2018-10-24	2020-04-30	F. Hoffmann-La Roche Ag	Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en)	2018-12-10	2020-06-18	Genentech, Inc.	Photocrosslinking peptides for site specific conjugation to fc-containing proteins
TWI853863B (zh)	2018-12-13	2024-09-01	日商衛材R&D企管股份有限公司	荷伯希二烯(herboxidiene)剪接調節抗體-藥物結合物及其使用方法
US11702482B2 (en)	2018-12-17	2023-07-18	Revitope Limited	Twin immune cell engager
GB201901197D0 (en)	2019-01-29	2019-03-20	Femtogenix Ltd	G-A Crosslinking cytotoxic agents
ES2967878T3 (es)	2019-03-15	2024-05-06	Medimmune Ltd	Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
GB2597532A (en)	2020-07-28	2022-02-02	Femtogenix Ltd	Cytotoxic compounds
KR20240095442A (ko)	2021-11-03	2024-06-25	항저우 디에이씨 바이오테크 씨오, 엘티디	항체의 특이적 접합
CN120417934A (zh)	2022-12-23	2025-08-01	基因泰克公司	Cereblon降解剂缀合物及其用途
CN121263210A (zh)	2023-04-17	2026-01-02	沛科生物公司	抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
TW202542189A (zh) *	2023-12-19	2025-11-01	德商拜恩技術股份公司	Cfc1結合分子
TW202532437A (zh) *	2023-12-19	2025-08-16	德商拜恩技術股份公司	Cfc1結合分子
WO2026006689A2 (en)	2024-06-28	2026-01-02	Firefly Bio, Inc.	Bcl-xl degrader antibody conjugates and uses thereof
WO2026006688A2 (en)	2024-06-28	2026-01-02	Firefly Bio, Inc.	Degrader antibody conjugates and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ207394A (en) *	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5208020A (en) *	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5780029A (en)	1989-11-14	1998-07-14	New York Medical College	Antidiotypic monoclonal antibodies for treatment of melanoma
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5256643A (en)	1990-05-29	1993-10-26	The Government Of The United States	Human cripto protein
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US5264557A (en)	1991-08-23	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Polypeptide of a human cripto-related gene, CR-3
US6063379A (en)	1993-12-09	2000-05-16	Centro De Inmunologia Molecular	Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
US5981215A (en) *	1995-06-06	1999-11-09	Human Genome Sciences, Inc.	Human criptin growth factor
WO1997044461A2 (en) *	1996-05-22	1997-11-27	Novopharm Biotech, Inc.	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
IL125608A0 (en)	1998-07-30	1999-03-12	Yeda Res & Dev	Tumor associated antigen peptides and use of same as anti-tumor vaccines
HRP20010551B1 (hr)	1998-12-23	2013-05-31	Pfizer Inc.	Humana monoklonalna antitijela za ctla-4
WO2000052204A2 (en)	1999-02-22	2000-09-08	Orntoft Torben F	Gene expression in bladder tumors
WO2000058499A1 (fr)	1999-03-30	2000-10-05	Japan Tobacco Inc.	Procede pour la production d'anticorps monoclonal
CA2370760A1 (en) *	1999-04-20	2000-10-26	William J. Kokolus	Improved method of identifying and locating immunobiologically-active linear peptides
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2001046066A (ja)	1999-08-03	2001-02-20	Kyowa Hakko Kogyo Co Ltd	新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
NZ518477A (en)	1999-10-29	2004-10-29	Genentech Inc	Isolated anti-prostate stem cell antigen (PSCA) antibodies that internalise upon binding to PSCA on a mammalian cell, including a PSCA-expressing tumour cell, in vivo
US6663613B1 (en)	2000-01-25	2003-12-16	Bacchus Vascular, Inc.	System and methods for clot dissolution
DE60134962D1 (de) *	2000-03-03	2008-09-04	Kyowa Hakko Kogyo Kk	Anti-ccr4 antikörper und fragmente davon
US6333410B1 (en) *	2000-08-18	2001-12-25	Immunogen, Inc.	Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en)	2000-08-24	2000-10-11	Smithkline Beecham Biolog	Vaccine
CA2422814A1 (en)	2000-09-18	2002-03-21	Biogen, Inc.	Cripto mutant and uses thereof
ES2278899T3 (es)	2001-01-26	2007-08-16	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	Deteccion y cuantificacion de cripto-1.
AU2002327164A1 (en)	2001-01-29	2002-12-09	Idec Pharmaceuticals Corporation	Engineered tetravalent antibodies and methods of use
CN1494553A (zh)	2001-01-29	2004-05-05	IDECҩ�﹫˾	改变的抗体及其使用方法
AUPR395801A0 (en)	2001-03-26	2001-04-26	Austin Research Institute, The	Antibodies against cancer
US7582299B2 (en) *	2001-04-26	2009-09-01	Biogen Idec Ma Inc.	Cripto-specific antibodies
ATE420659T1 (de)	2001-04-26	2009-01-15	Biogen Idec Inc	Criptoblockierende antikörper und deren verwendung
EP2151244A1 (en) *	2001-09-18	2010-02-10	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US20040014690A1 (en)	2002-02-13	2004-01-22	Zhenkun Ma	Macrolides with activity against methicillin-resistant staphylococcus aureus
EP1494693B1 (en) *	2002-03-22	2010-12-08	Biogen Idec MA Inc.	Cripto-specific antibodies
WO2005028433A2 (en) *	2003-09-15	2005-03-31	Research Development Foundation	CRIPTO ANTAGONISM OF ACTIVIN AND TGF-β SIGNALING
KR20070100346A (ko)	2005-01-05	2007-10-10	바이오겐 아이덱 엠에이 인코포레이티드	크립토 결합 분자
CN101479391A (zh) *	2006-04-28	2009-07-08	比奥根艾迪克Ma公司	用于检测cripto-3的组合物及方法

2002
- 2002-04-17 AT AT02731384T patent/ATE420659T1/de active
- 2002-04-17 MX MXPA03009797A patent/MXPA03009797A/es active IP Right Grant
- 2002-04-17 EA EA200301158A patent/EA007469B1/ru not_active IP Right Cessation
- 2002-04-17 JP JP2002585468A patent/JP4307845B2/ja not_active Expired - Fee Related
- 2002-04-17 CA CA2443840A patent/CA2443840C/en not_active Expired - Fee Related
- 2002-04-17 TR TR2003/01846T patent/TR200301846T2/xx unknown
- 2002-04-17 EP EP02731384A patent/EP1390389B1/en not_active Expired - Lifetime
- 2002-04-17 KR KR1020037014078A patent/KR100592357B1/ko not_active Expired - Fee Related
- 2002-04-17 EE EEP200300528A patent/EE200300528A/xx unknown
- 2002-04-17 SI SI200230804T patent/SI1390389T1/sl unknown
- 2002-04-17 HU HU0501113A patent/HUP0501113A3/hu unknown
- 2002-04-17 SG SG200600551-6A patent/SG157951A1/en unknown
- 2002-04-17 GE GE5415A patent/GEP20074091B/en unknown
- 2002-04-17 EP EP08158456A patent/EP1974749B1/en not_active Expired - Lifetime
- 2002-04-17 BR BRPI0209254-9A patent/BR0209254A/pt not_active IP Right Cessation
- 2002-04-17 WO PCT/US2002/011950 patent/WO2002088170A2/en not_active Ceased
- 2002-04-17 EP EP10186149A patent/EP2316486A3/en not_active Withdrawn
- 2002-04-17 RS RS20110024A patent/RS20110024A/sr unknown
- 2002-04-17 DE DE60230868T patent/DE60230868D1/de not_active Expired - Lifetime
- 2002-04-17 DK DK02731384T patent/DK1390389T3/da active
- 2002-04-17 AT AT08158456T patent/ATE533508T1/de active
- 2002-04-17 SK SK1443-2003A patent/SK14432003A3/sk not_active Application Discontinuation
- 2002-04-17 ES ES02731384T patent/ES2321065T3/es not_active Expired - Lifetime
- 2002-04-17 RS YU84903A patent/RS51635B/sr unknown
- 2002-04-17 PT PT02731384T patent/PT1390389E/pt unknown
- 2002-04-17 NZ NZ566268A patent/NZ566268A/en not_active IP Right Cessation
- 2002-04-17 CA CA2715570A patent/CA2715570A1/en not_active Abandoned
- 2002-04-17 CN CNB028128877A patent/CN100352501C/zh not_active Expired - Fee Related
- 2002-04-17 CZ CZ20033208A patent/CZ20033208A3/cs unknown
- 2002-04-17 PL PL373513A patent/PL207087B1/pl unknown
- 2002-04-23 MY MYPI2010003173A patent/MY150237A/en unknown
- 2002-04-23 MY MYPI20021484A patent/MY157382A/en unknown
- 2002-04-24 AR ARP020101492A patent/AR037223A1/es active IP Right Grant
2003
- 2003-10-23 US US10/693,538 patent/US7531174B2/en not_active Expired - Lifetime
- 2003-10-24 IS IS6999A patent/IS2662B/is unknown
- 2003-10-27 NO NO20034805A patent/NO20034805L/no not_active Application Discontinuation
- 2003-11-14 BG BG108363A patent/BG108363A/bg unknown
2005
- 2005-07-11 JP JP2005202361A patent/JP2005314436A/ja active Pending
2007
- 2007-04-30 US US11/799,361 patent/US7674462B2/en not_active Expired - Lifetime
2008
- 2008-12-22 US US12/317,476 patent/US8003763B2/en not_active Expired - Lifetime
2009
- 2009-01-14 US US12/353,913 patent/US20090285818A1/en not_active Abandoned
- 2009-02-05 JP JP2009025420A patent/JP4575983B2/ja not_active Expired - Fee Related
- 2009-03-31 US US12/415,659 patent/US7888052B2/en not_active Expired - Lifetime
- 2009-04-08 CY CY20091100413T patent/CY1108960T1/el unknown
- 2009-07-08 AR ARP090102597A patent/AR072554A2/es not_active Application Discontinuation
- 2009-12-22 CL CL2009002199A patent/CL2009002199A1/es unknown
2010
- 2010-02-15 JP JP2010030683A patent/JP2010163438A/ja not_active Withdrawn
- 2010-07-16 AR ARP100102604A patent/AR077759A2/es not_active Application Discontinuation
2011
- 2011-08-19 US US13/213,499 patent/US8673303B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE60230868D1 (de)	2009-03-05
EP1390389B1 (en)	2009-01-14
US20040146940A1 (en)	2004-07-29
US20080166341A1 (en)	2008-07-10
JP2009108100A (ja)	2009-05-21
SG157951A1 (en)	2010-01-29
SI1390389T1 (sl)	2009-06-30
WO2002088170A2 (en)	2002-11-07
KR20040028744A (ko)	2004-04-03
NO20034805D0 (no)	2003-10-27
MY157382A (en)	2016-06-15
CA2443840A1 (en)	2002-11-07
EP1390389A2 (en)	2004-02-25
AR072554A2 (es)	2010-09-08
JP4575983B2 (ja)	2010-11-04
NZ566268A (en)	2009-09-25
PT1390389E (pt)	2009-04-03
CA2715570A1 (en)	2002-11-07
JP4307845B2 (ja)	2009-08-05
ATE420659T1 (de)	2009-01-15
NO20034805L (no)	2003-12-23
IS2662B (is)	2010-08-15
EP1390389A4 (en)	2004-09-22
EE200300528A (et)	2004-08-16
KR100592357B1 (ko)	2006-06-22
EP1974749B1 (en)	2011-11-16
US20090285818A1 (en)	2009-11-19
HUP0501113A3 (en)	2007-12-28
GEP20074091B (en)	2007-04-25
AR037223A1 (es)	2004-11-03
CY1108960T1 (el)	2014-07-02
RS51635B (sr)	2011-08-31
HK1058935A1 (en)	2004-06-11
MXPA03009797A (es)	2004-01-29
US7531174B2 (en)	2009-05-12
JP2010163438A (ja)	2010-07-29
IS6999A (is)	2003-10-24
JP2005314436A (ja)	2005-11-10
YU84903A (sh)	2006-05-25
PL373513A1 (en)	2005-09-05
TR200301846T2 (tr)	2006-10-26
BG108363A (bg)	2004-09-30
US8003763B2 (en)	2011-08-23
CA2443840C (en)	2010-10-26
CN100352501C (zh)	2007-12-05
CL2009002199A1 (es)	2010-05-07
EP2316486A2 (en)	2011-05-04
US20120195912A1 (en)	2012-08-02
CN1606453A (zh)	2005-04-13
PL207087B1 (pl)	2010-10-29
SK14432003A3 (sk)	2004-07-07
EA200301158A1 (ru)	2005-06-30
HUP0501113A2 (en)	2007-05-02
US7888052B2 (en)	2011-02-15
MY150237A (en)	2013-12-31
EP1974749A1 (en)	2008-10-01
ES2321065T3 (es)	2009-06-02
US8673303B2 (en)	2014-03-18
US20100202962A1 (en)	2010-08-12
BR0209254A (pt)	2006-10-03
RS20110024A (sr)	2011-08-31
EP2316486A3 (en)	2011-09-07
US20090286265A1 (en)	2009-11-19
WO2002088170A3 (en)	2003-12-24
EA007469B1 (ru)	2006-10-27
ATE533508T1 (de)	2011-12-15
AR077759A2 (es)	2011-09-21
JP2004534020A (ja)	2004-11-11
CZ20033208A3 (en)	2004-03-17
US7674462B2 (en)	2010-03-09

Publication	Publication Date	Title
DK1390389T3 (da)	2009-04-20	Cripto-blokerende antistoffer og anvendelser deraf
EP1412378A4 (en)	2006-09-20	APTAMERS AND ANTIAPTAMERS
DK1417175T3 (da)	2013-10-28	Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1746375T3 (da)	2013-02-11	Oxygendrevet forbrændingssystem og anvendelser deraf
NO20034405L (no)	2003-12-05	Anti-ostepontin-antistoff og anvendelse derav
NO20030614L (no)	2003-04-02	Anti-IL-12-antistoffer, sammensetninger, fremgangsmåter og anvendelser
EP1298180A4 (en)	2005-03-09	HYDROPHOBIC AND LIPOPHOBE COMPOSITION
NO20033387L (no)	2003-09-25	Modifiserte antistoffer og fremgangsmåter for anvendelse
PT1411764E (pt)	2005-05-31	Cerca
DK2418220T3 (da)	2017-11-06	Interferon-alpha-antistoffer og anvendelser deraf
DK1562968T3 (da)	2013-10-28	Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser
DE60212600D1 (de)	2006-08-03	Audiocodierung und decodierung
NO20033418L (no)	2003-09-30	Immunregulatoriske antistoffer og anvendelse derav
DK1370128T3 (da)	2014-05-26	Kombineret ballepresse og ballevikler
NO20034159L (no)	2003-09-18	Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
FR2823558B1 (fr)	2005-10-21	Glaciere portable
DE60220486D1 (de)	2007-07-19	Zurückschaltungseinrichtung und Zurückschaltungsverfahren
NO20021786L (no)	2003-04-03	Skumdempningsfremgangsmåter og sammensetninger
EE200300569A (et)	2004-04-15	CD44v6-spetsiifilised antikehad
EP1351388A4 (en)	2009-06-17	PHASE SLIDER AND MULTIBIT PHASE SLIDER
DE60204749D1 (de)	2005-07-28	Abtast- und Halteschaltung
NO20022626D0 (no)	2002-06-03	Reagenser og komplekser
DE50200752D1 (de)	2004-09-09	Mikrotom
DE60205008D1 (de)	2005-08-18	Kettelverfahren und -vorrichtung
DE60219418D1 (de)	2007-05-24	Silanylphenole und -naphthole